Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Impact of HIV infection, highly active antiretroviral therapy, and hepatitis C coinfection on serum interleukin-27.

Guzzo C, Hopman WM, Che Mat NF, Wobeser W, Gee K.

AIDS. 2010 Jun 1;24(9):1371-4. doi: 10.1097/QAD.0b013e3283391d2b.

PMID:
20375875
2.

Impaired recovery of CD4+ cell counts following highly active antiretroviral therapy in drug-naïve patients coinfected with human immunodeficiency virus and hepatitis C virus.

Macías J, Pineda JA, Lozano F, Corzo JE, Ramos A, León E, García-García JA, Fernández-Rivera J, Mira JA, Gómez-Mateos J.

Eur J Clin Microbiol Infect Dis. 2003 Nov;22(11):675-80.

PMID:
14574616
3.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
4.
5.

Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects.

De Luca A, Bugarini R, Lepri AC, Puoti M, Girardi E, Antinori A, Poggio A, Pagano G, Tositti G, Cadeo G, Macor A, Toti M, D'Arminio Monforte A; Italian Cohort Naive Antiretrovirals Study Group..

Arch Intern Med. 2002 Oct 14;162(18):2125-32.

PMID:
12374521
6.

Interleukin-7 (IL-7): immune function, involvement in the pathogenesis of HIV infection and therapeutic potential.

Beq S, Delfraissy JF, Theze J.

Eur Cytokine Netw. 2004 Oct-Dec;15(4):279-89. Review.

7.

Immunologic dynamics in hemophiliac patients infected with hepatitis C virus and human immunodeficiency virus: influence of antiretroviral therapy.

Yokozaki S, Takamatsu J, Nakano I, Katano Y, Toyoda H, Hayashi K, Hayakawa T, Fukuda Y.

Blood. 2000 Dec 15;96(13):4293-9.

8.

Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection.

Plana M, García F, Gallart T, Tortajada C, Soriano A, Palou E, Maleno MJ, Barceló JJ, Vidal C, Cruceta A, Miró JM, Gatell JM.

AIDS. 2000 Sep 8;14(13):1921-33.

PMID:
10997396
9.

Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a nationwide cohort study.

Weis N, Lindhardt BO, Kronborg G, Hansen AB, Laursen AL, Christensen PB, Nielsen H, Moller A, Sorensen HT, Obel N.

Clin Infect Dis. 2006 May 15;42(10):1481-7.

10.

Analysis of the effect of highly active antiretroviral therapy during acute HIV-1 infection on HIV-specific CD4 T cell functions.

Jansen CA, De Cuyper IM, Steingrover R, Jurriaans S, Sankatsing SU, Prins JM, Lange JM, van Baarle D, Miedema F.

AIDS. 2005 Jul 22;19(11):1145-54.

PMID:
15990567
11.

Relationship between human T lymphotropic virus (HTLV) type 1/2 viral burden and clinical and treatment parameters among patients with HIV type 1 and HTLV-1/2 coinfection.

Beilke MA, Traina-Dorge VL, Sirois M, Bhuiyan A, Murphy EL, Walls JM, Fagan R, Winsor EL, Kissinger PJ.

Clin Infect Dis. 2007 May 1;44(9):1229-34.

12.

IL-2 and IL-10 serum levels in HIV-1-infected patients with or without active antiretroviral therapy.

Orsilles MA, Pieri E, Cooke P, Caula C.

APMIS. 2006 Jan;114(1):55-60.

PMID:
16499662
13.

Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy.

Castagna A, Galli L, Torti C, D'Arminio Monforte A, Mussini C, Antinori A, Cozzi-Lepri A, Ladisa N, De Luca A, Seminari E, Gianotti N, Lazzarin A.

Antivir Ther. 2010;15(2):165-75. doi: 10.3851/IMP1513.

PMID:
20386071
14.

Longitudinal study in HIV/HCV-coinfected HAART-naive patients and role of HCV genotype.

Caudai C, Pianese M, Zacchini F, Toti M, Zazzi M, Valensin PE.

J Clin Virol. 2005 Feb;32(2):151-5.

PMID:
15653418
15.
16.

Impact of hepatitis C virus coinfection on immune restoration during successful antiretroviral therapy in chronic human immunodeficiency virus type 1 disease.

Santin M, Mestre M, Shaw E, Barbera MJ, Casanova A, Niubo J, Bolao F, Podzamczer D, Gudiol F.

Eur J Clin Microbiol Infect Dis. 2008 Jan;27(1):65-73.

PMID:
17938979
17.

Interleukin-2 therapy restores CD8 cell non-cytotoxic anti-HIV responses in primary infection subjects receiving HAART.

Martinez-Mariño B, Shiboski S, Hecht FM, Kahn JO, Levy JA.

AIDS. 2004 Oct 21;18(15):1991-9.

PMID:
15577620
18.

Slower progression of HIV-1 infection in persons with GB virus C co-infection correlates with an intact T-helper 1 cytokine profile.

Nunnari G, Nigro L, Palermo F, Attanasio M, Berger A, Doerr HW, Pomerantz RJ, Cacopardo B.

Ann Intern Med. 2003 Jul 1;139(1):26-30.

PMID:
12834315
19.

Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.

Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, Viganò P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD; HepaI.Co.N.A. Study Group.; Italian Cohort Naive for Antiretrovirals Study Group..

Clin Infect Dis. 2005 Jun 15;40(12):e101-9.

20.

Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study--ANRS 082.

Katlama C, Carcelain G, Duvivier C, Chouquet C, Tubiana R, De Sa M, Zagury L, Calvez V, Autran B, Costagliola D; ILSTIM..

AIDS. 2002 Oct 18;16(15):2027-34.

PMID:
12370501
Items per page

Supplemental Content

Support Center